CFN Media Group ("CannabisFN"), the leading creative agency and
media network dedicated to legal cannabis, announces publication of
an article covering India Globalization Capital
Inc’s (NYSE American: IGC) Hyalolex, a cannabinoid-based
therapy that appears to act on many different hypotheses of disease
modalities. Investors interested in the AD space may want to take a
closer look at the stock.
Alzheimer’s disease has already become the sixth
leading cause of death in the United States and could cost the
healthcare system upwards of $1 trillion by 2050. While
pharmaceutical companies have spent billions of dollars trying to
cure the disease, experts still aren’t sure exactly what causes the
condition and how to go about treating it. The good news is that
there are some therapeutics that act on multiple potential
underlying causes.
Elusive Alzheimer’s Treatments
Alzheimer’s disease affects over five million
people in the United States and has become the sixth leading cause
of death. Last year, the disease and related dementias cost the
country $260 billion and is projected to cost about $1.1 trillion
by 2050. It is America’s most expensive disease. About 10% of
people over 65 are diagnosed with Alzheimer’s, and almost 66% of
Alzheimer’s patients are women. At the same time, 35% of caregivers
report that their health has gotten worse due to their care
responsibilities, adding even further to the costs associated with
the disease.
While there are several drugs that treat
Alzheimer’s disease, the quest to cure the illness has frustrated
even the largest pharmaceutical companies. The consensus for the
past 25 years has been that the disease is caused by the build-up
of a sticky plaque called beta amyloid in the brain. Billions of
dollars were subsequently spent developing drugs to clear beta
amyloid, but all of them have failed at various stages of clinical
trials.
Some companies are shifting their focus to tau
proteins, which get twisted and block the internal transport system
of neurons. While one clinical trial focused on these proteins
failed, the research remains in the early stages of clinical
trials. Other researchers believe that over-reactive oxygen
molecules are causing oxidative stress, which could lead to the
build-up of beta amyloid plaque and other “symptoms” of the
disease.
How Cannabis Could Help
India Globalization Capital’s Hyalolex (IGC-AD1)
has been shown to act on many of these different pathways in early
research studies. In addition to modulating beta amyloid production
and inhibiting aggregation, the compound appears to inhibit
hyperphosphorylation of tau proteins, enhance mitochondrial
function, and modulate several endpoints of AD. The compound is
also non-toxic to neurons and doesn’t product a “high” feeling.
Using an immunoblotting technique, Dr. Chuanhai
Cao demonstrated that IGC-AD1 inhibits beta amyloid aggregation in
a dose-dependent manner by increasing monomer levels. This
addresses the “amyloid hypothesis” that states that the aggregation
of amyloids into toxic oligomers is a key pathogenic event in the
onset of AD. These plaques could also trigger other pathological
events, such as oxidative damage and inflammation.
The same technique of using immunoblotting showed
that IGC-AD1 reduced the expression of an enzyme that enables
phosphorylation by as much as 53% to 62%, which reverses some of
the pathological effects of overexpressed APP and tau proteins.
This addresses the “tau protein hypothesis” that states that tau
protein phosphorylation is three to four times higher than a normal
brain, which could be the underlying cause of AD.
Finally, Dr. Cao showed that IGC-AD1 enhanced
mitochondrial function by between 30% and 60%, which could address
the “mitochondrial cascade hypothesis”. This hypothesis is based on
the notion that mitochondrial dysfunction - which worsens with age
naturally - could start a cascade that ultimately leads to the
disease. Evidence has also shown that elevated beta amyloid levels
contribute to these mitochondrial abnormalities.
Other than the evidence showing that Hyalolex may
address the three disease etiological hypothesis as outlined above,
Hyalolex at larger doses may reduce patient anxiety, patient
aggression, sleep disorder and alleviate overall caregiver
distress.
Commercialization Strategy
Hyalolex is a liquid formulation that comprises of
cannabis extracts, including THC, along with other natural
compounds. It will be prescribed in two different doses. The
smaller dose for mild to moderate AD patients, and the larger dose
for moderate to advanced patients. IGC plans to distribute its
technology through licensed medical cannabis dispensaries in the
United States. This process will include state-by-state sourcing,
formula assembly, packaging, and distribution utilizing best
practices to ensure quality control while complying with the
current legal guidelines established by each individual state.
Management plans to begin the rollout in the first
half of this year in Washington D.C., Maryland, and California
dispensaries. To help facilitate the rollout, the company engaged
The Medical Marketing Group inc., a provider of outsourced
product-detailing, education, and outreach services. The company
projects the rollout of Hyalolex in 10 of the 29 legal states in
2018.
In addition to its launch across dispensaries, the
company is preparing the groundwork necessary for Phase 2B human
trials with the U.S. Food and Drug Administration (FDA). The
company’s most recent results showed compelling in vivo data from
genetically engineered mice, including marked 50% improvement in
spatial memory. If these results translate to humans, the drug
program could be groundbreaking within the industry.
Please follow the link to read the full
article:
http://www.cannabisfn.com/india-globalizations-hyalolex-shows-promise-treating-patients-alzheimers-disease/
For more information, visit the company’s website
at http://www.igcinc.us/.
About CFN Media
CFN Media (CannabisFN) is the leading creative
agency and media network dedicated to legal cannabis. We help
marijuana businesses attract investors, customers (B2B, B2C),
capital, and media visibility. Private and public marijuana
companies and brands in the US and Canada rely on CFN Media to grow
and succeed.
Learn how to become a CFN Media client company,
brand or
entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access
the world of cannabis from the palm of your
hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number
under the Apple App Store logo to receive a download link text on
your iPhone:http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial
investment advisor or broker-dealer. You should always consult with
your own independent legal, tax, and/or investment professionals
before making any investment decisions. The information provided
on http://www.cannabisfn.com (the ‘Site’) is either
original financial news or paid advertisements drafted by our
in-house team or provided by an affiliate. CannabisFN.com, a
financial news media and marketing firm enters into media buys or
service agreements with the companies that are the subject of the
articles posted on the Site or other editorials for advertising
such companies. We are not an independent news media
provider. We make no warranty or representation about the
information including its completeness, accuracy, truthfulness or
reliability and we disclaim, expressly and implicitly, all
warranties of any kind, including whether the Information is
complete, accurate, truthful, or reliable. As such, your use of the
information is at your own risk. Nor do we undertake any obligation
to update the items posted. CannabisFN.com received compensation
for producing and presenting high quality and sophisticated content
on CannabisFN.com along with financial and corporate
news.
The above article is sponsored content. Emerging
Growth LLC, which owns CannabisFN.com and CFN Media, has been hired
to create awareness. Please follow the link below to view our full
disclosure outlining our
compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com